Vitros 950 chemistry station

Systolic (SBP) and diastolic blood pressure (DBP) were measured according to Canadian Hypertensive Education Program recommendations [17 (link)]. Fasting plasma glucose was quantified by spectrophotometric assay (Vitros 950 Chemistry Station, Ortho-Clinical Diagnostics, Raritan, NJ, USA), and fasting plasma insulin, by immunoassay with chemiluminescent detection (Advia Centaur, Siemens, Washington, DC, USA). Homeostatic model assessment 2 of insulin resistance (HOMA2-IR) was calculated from fasting plasma glucose and insulin levels [18 (link)]. Triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C) were evaluated by enzymatic methods (Vitros 950 Chemistry Station, Ortho-Clinical Diagnostics). TG/HDL-C ratio was ascertained by dividing TG by HDL-C concentrations. Lipids were not assessed in participants aged 8 to 14 years during the 2005 (1 community) and 2007 (2 communities) surveys, which corresponded to missing values for 91 participants.

Cholesterol and triacylglycerol (TG) levels were measured by enzymatic methods in a Vitros 950 Chemistry Station (Ortho-Clinical Diagnostics, Raritan, NJ). HDL-cholesterol (HDL-c) was assessed directly with a Roche HDL-c plus third-generation reagent. LDL-cholesterol (LDL-c) was calculated by Friedewald's formula. Apolipoproteins (apo) A1 and B-100 were quantified by nephelometry in a BN ProSpec station (Dade Behring, Mississauga, ON). Fasting plasma glucose was measured enzymatically and fasting plasma insulin concentrations were measured with a commercial double-antibody radioimmunoassay (RIA) as described by Dewailly et al. (16 (link)). The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated using the formula fasting plasma glucose (mmol/l)×fasting plasma insulin (mU/l)/22.5.